Xprecia StrideTM Coagulation Analyzer
Following on from its successful
validation with glucose, UBI has adapted its electrochemical
cell to measure Prothrombin Time (PT/INR), a test used to monitor the
anticoagulant therapy warfarin. The test is used to maintain patients on a safe
and effective dose. If patients are taking too much warfarin they are at risk
of serious bleeding events and if too little they are at risk of
UBI has signed a long term supply
and manufacturing agreement with Siemens Healthcare Diagnostics to manufacture
three test strips for the professional point-of-care coagulation testing market.
The first product, a PT/INR test, was launched in December 2014. UBI is
also developing its own PT/INR device for use in decentralised settings including
the patient self-test market.
Read more about PT/INR
With UBI's test
strip technology now demonstrated in blood glucose, and coagulation testing the
company is focused on adding new clinically relevant and commercially
attractive tests to its product pipeline.
Read more about Immunoassay
UBI is developing an immunoassay-based system (an important technique for
biomarker measurement), which is progressing through the feasibility stage of
the company's R&D pipeline. Another key opportunity is UBI's early
but exciting research into molecular diagnostics testing.